Management of Kaposi's sarcoma in resource-limited settings in the era of HAART

AIDS Reviews

Volumn 7, Issue 1, 2005, Pages 13-21

  Lynen, Lut ^a   Zolfo, Maria ^a   Huyst, Veerle ^a   Louis, Francoise ^b   Barnardt, Pieter ^c   de Velde, Ann ^d   De Schacht, Caroline ^a   Colebunders, Robert ^a,d,e  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b MÉDECINS SANS FRONTIÈRES   (Belgium)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e MULAGO HOSPITAL   (Uganda)

Author keywords

AIDS; Developing countries; HAART; Kaposi's sarcoma; Resource limited settings

Indexed keywords

ALITRETINOIN; ALPHA INTERFERON; ANTIRETROVIRUS AGENT; BLEOMYCIN; CORTICOSTEROID; DAUNORUBICIN; DIDANOSINE; DOXORUBICIN; ETOPOSIDE; METRONIDAZOLE; PACLITAXEL; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANAPHYLAXIS; ANEMIA; APPETITE DISORDER; AREFLEXIA; ASTHENIA; BONE MARROW SUPPRESSION; CHILL; CLINICAL FEATURE; CONFUSION; CONSTIPATION; DEVELOPING COUNTRY; DISEASE EXACERBATION; DRUG COST; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; EXTRAVASATION; FEVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOREFLEXIA; HYPOTENSION; ILEUS; INJECTION PAIN; KAPOSI SARCOMA; LIVER DYSFUNCTION; LUNG FIBROSIS; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; RAYNAUD PHENOMENON; REVIEW; RIGOR; SENSORIMOTOR NEUROPATHY; SKIN IRRITATION; SKIN MANIFESTATION; THROMBOCYTOPENIA; TISSUE NECROSIS; TREATMENT INDICATION; WHEEZING;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEVELOPING COUNTRIES; HIV INFECTIONS; HUMANS; SARCOMA, KAPOSI;

EID: 18744368512     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. WHO. Treating 3 million people in the developing world by 2005. WHO 2003 (Available from URL: http://www.who.int/3by5/publications/documents/en /3by5StrategyMakingItHappen.pdf). Accessed Dec 2004.
2. The Global Fund to fight AIDS, Tuberculosis and Malaria. THE GLOBAL FUND 2004 (Available from URL: http://www.theglobalfund.org/en/). Accessed Dec 2004.
3. Dupont C, Vasseur E, Beauchet A, et al. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. AIDS 2000;14:987-93.
4. Jones J, Hanson D, Dworkin M, Ward J, Jaffe H. Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons. Adult/Adolescent Spectrum of HIV Disease Project Group. J Acquir Immune Defic Syndr 1999;21 Suppl 1:S11-7.
5. Hengge U, Ruzicka T, Tyring S, et al. Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis 2002;2:281-92.
6. Dal Maso L, Serraino D, Franceschi S. Epidemiology of AIDS-related tumours in developed and developing countries. Eur J Cancer 2001;37:1188-201.
7. Orem J, Otieno M, Remick S. AIDS-associated cancer in developing nations. Curr Opin Oncol 2004;16:468-76.
8. Ablashi D, Chatlynne L, Cooper H, et al. Seroprevalence of human herpesvirus-8 (HHV-8) in countries of Southeast Asia compared to the USA, the Caribbean and Africa. Br J Cancer 1999;81:893-7.
9. Jing W, Ismail R. Mucocutaneous manifestations of HIV infection: a retrospective analysis of 145 cases in a Chinese population in Malaysia. Int J Dermatol 1999;38:457-63.
10. Jacobson L, Yamashita T, Detels R, et al. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1999;21 (suppl):34-41.
11. Ledergerber B, Telenti A, Egger M. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. Swiss HIV Cohort Study. BMJ 1999;319:23-4.
12. Mocroft A, Kirk O, Clumeck N, et al. The changing pattern of Kaposi's sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study. Cancer 2004;100:2644-54.
13. Bourboulia D, Aldam D, Lagos D, et al. Short- and long-term effects of highly active antiretroviral therapy on Kaposi's sarcoma-associated herpesvirus immune responses and viraemia. AIDS 2004; 18:485-93.
14. Trattner A, Hodak E, David M, Sandbank M. The appearance of Kaposi's sarcoma during corticosteroid therapy. Cancer 1993; 72: 1779-83.
15. Nasti G, Talamini R, Antinori A, et al. AIDS-related Kaposi's sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the HAART Era - the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals. J Clin Oncol 2003;21:2876-82.
16. Martin-Carbonero L, Barrios A, Saballs P, et al. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS 2004;18:1737-40.
17. Gill J, Bourboulia D, Wilkinson J, et al. Prospective study of the effects of antiretroviral therapy on Kaposi's sarcoma-associated herpesvirus infection in patients with and without Kaposi's sarcoma. J Acquir Immune Defic Syndr 2002;31:384-90.
18. Portsmouth S, Stebbing J, Gill J, et al. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. AIDS 2003;17: F17-F22.
19. Paparizos V, Kyriakis K, Papastamopoulos V, Hadjivassiliou M, Stavrianeas N. Response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy alone. J Acquir Immune Defic Syndr 2002;30:257-8.
20. Pellet C, Chevret S, Blum L, et al. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy. J Invest Dermatol 2001;117:858-63.
21. Bower M, Fox P, Fife K, Gill J, Nelson M, Gazzard B. Highly active antiretroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS 1999;13:2105-11.
22. Cattelan A, Calabro M, Gasperini P, et al. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome. J Natl Cancer Inst Monogr 2001;28:44-9.
23. Shelburne S, Hamill R, Rodriguez-Barradas M, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Balt) 2002; 81:213-27.
24. Kedes D, Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest 1997;99:2082-6.
25. Boudreaux A, Smith L, Cosby C, Bason M, Tappero J, Berger T. Intralesional vinblastine for cutaneous Kaposi's sarcoma associated with acquired immunodeficiency syndrome. A clinical trial to evaluate efficacy and discomfort associated with infection. J Am Acad Dermatol 1993;28:61-5.
26. Brambilla L, Boneschi V, Beretta G, Finzi AF. Intralesional chemotherapy for Kaposi's sarcoma. Dermatologica 1984;169:150-5.
27. Tappero J, Berger T, Kaplan L, Volberding P, Kahn J. Cryotherapy for cutaneous Kaposi's sarcoma (KS) associated with acquired immune deficiency syndrome (AIDS): a phase II trial. J Acquir Immune Defic Syndr 1991;4:839-46.
28. Levine A. AIDS-related malignancies in the era of HAART. Medscape HIV/AIDS (Available from URL: http://www.medscape.com/viewarticle/418953).
29. Swift P. The role of radiation therapy in the management of HIV-related Kaposi's sarcoma. Hematol Oncol Clin North Am 1996;10: 1069-80.
30. Stelzer K, Griffin T. A randomized prospective trial of radiation therapy for AIDS-associated Kaposi's sarcoma. Int J Radiat Oncol Biol Phys 1993;27:1057-61.
31. Schöfer H. Kaposi's sarcoma. In: Hoffman C, Kamps B, editors. HIV Med 2003.
32. Lassoued K, Clauvel J, Katlama C, Janier M, Picard C, Matheron S. Treatment of the acquired immune deficiency syndrome-related Kaposi's sarcoma with bleomycin as a single agent. Cancer 1990; 66:1869-72.
33. Dezube B, Groopman J. AIDS-related Kaposi's sarcoma: clinical features and treatment. UpToDate 2005.
34. Shepherd F, Beaulieu R, Gelmon K, et al. Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with HIV infection: a Canadian HIV Clinical Trials Network study. J Clin Oncol 1998; 16:1736-42.
35. Stewart S, Jablonowski H, Goebel F, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol 1998;16:683-91.
36. Gill P, Wernz J, Scadden D, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996; 14:2353-64.
37. Esdaile B, Davis M, Portsmouth S, et al. The immunological effects of concomitant highly active antiretroviral therapy and liposomal anthracycline treatment of HIV-1-associated Kaposi's sarcoma. AIDS 2002;16:2344-7.
38. Sprinz E, Caldas A, Mans D, et al. Fractionated doses of oral etoposide in the treatment of patients with aids-related Kaposi's sarcoma: a clinical and pharmacologic study to improve therapeutic index. Am J Clin Oncol 2001;24:177-84.
39. Evans S, Krown S, Testa M, Cooley T, Von Roenn J. Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study. J Clin Oncol 2002;20:3236-41.
40. Krown S. Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. J Clin Oncol 2004;22:399-402.
41. Dedicoat M, Vaithilingum M, Newton R. Treatment of Kaposi's sarcoma in HIV-1 infected individuals with emphasis on resource-poor settings. Cochrane Database Syst Rev 2003;3:CD003256.
42. Kaplan L, Abrams D, Volberding P. Treatment of Kaposi's sarcoma in acquired immunodeficiency syndrome with an alternating vincristine-vinblastine regimen. Cancer Treat Rep 1986;70:1121-2.
43. VEPESID. The comprehensive resource for physicians, drugs and illness information. VEPESID 2005 (Available from URL: http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs /CPS-%20Monographs/CPS-%20(General%20Monographs-%20V)/VEPESID.html
44. Weir A, Wansbrough-Jones M. Mucosal Kaposi's sarcoma following protease inhibitor therapy in an HIV-infected patient. AIDS 1997; 11:1895-6.
45. Rizos E, Drosos A, Ioannidis JP. Isolated intraparotid Kaposi's sarcoma in HIV type 1 infection. Mayo Clin Proc 2003;78:1561-3.
46. Connick E, Kane M, White I, Ryder J, Campbell T. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma during potent antiretroviral therapy. Clin Infect Dis 2004; 39:1852-5.
47. Shelburne S, Hamill R. The immune reconstitution inflammatory syndrome. AIDS Rev 2003;5:67-79.
48. Reiser M, Bruns C, Hartmann P, Salzberger B, Diehl V, Fatkenheuer G. Raynaud's phenomenon and acral necrosis after chemotherapy for AIDS-related Kaposi's sarcoma. Eur J Clin Microbiol Infect Dis 1998;17:58-60.
49. Pati S, Pelser C, Dufraine J, Bryant J, Reitz M, Weichold F. Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi's sarcoma. Blood 2002;99:3771-9.
50. Sgadari C, Barillari G, Toschi E, et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi's sarcoma. Nat Med 2002;8:225-32.
51. Krown S, Metroka C, Wernz J. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1989;7:1201-7.